表紙
市場調查報告書
商品編碼
913626

西尼羅河病毒治療藥的全球市場:2019年∼2023年

West Nile Virus Therapeutics Market by Application and Geography - Global Forecast & Analysis 2019-2023

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 152 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球西尼羅河病毒治療藥市場上,疾病的傳染性,店面銷售(OTC)治療藥的可得性,診斷試驗的可得性等成為成長促進因素,在預測期間內將以2%以上的年複合成長率擴大。可是,控制蚊子繁殖的計劃,已批准治療方法的缺乏,及疾病無症候的性質等要素,可能妨礙在預測期間內西尼羅河病毒治療藥產業的成長。

本報告提供全球西尼羅河病毒治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • 神經侵入性
  • 非神經侵入性
  • 市場機會:各應用領域

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 黃病毒科的流行病學的變化
  • 意識的高漲
  • 由於輸血增加感染擴大的風險

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Granules India Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR32148

About this market

Technavio's West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.

Overview

Availability of over-the-counter therapeutics

West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.

Rising awareness

In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.

For the detailed list of factors that will drive the global West Nile virus therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Neuroinvasive - Market size and forecast 2018-2023
  • Non-neuroinvasive - Market size and forecast 2018-2023
  • Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Shifting epidemiology of Flaviviridae
  • Rising awareness
  • Growing risk of spreading infections via blood transfusions

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • GlaxoSmithKline Plc
  • Granules India Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Co. Plc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Application - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by application
  • Exhibit 20: Neuroinvasive - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Neuroinvasive - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Non-neuroinvasive - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Non-neuroinvasive - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by application
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
  • Exhibit 49: Aurobindo Pharma Ltd. - Product segments
  • Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
  • Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
  • Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
  • Exhibit 53: Aurobindo Pharma Ltd. - Key customers
  • Exhibit 54: Bayer AG - Vendor overview
  • Exhibit 55: Bayer AG - Business segments
  • Exhibit 56: Bayer AG - Organizational developments
  • Exhibit 57: Bayer AG - Geographic focus
  • Exhibit 58: Bayer AG - Segment focus
  • Exhibit 59: Bayer AG - Key offerings
  • Exhibit 60: Bayer AG - Key customers
  • Exhibit 61: GlaxoSmithKline Plc - Vendor overview
  • Exhibit 62: GlaxoSmithKline Plc - Business segments
  • Exhibit 63: GlaxoSmithKline Plc - Organizational developments
  • Exhibit 64: GlaxoSmithKline Plc - Geographic focus
  • Exhibit 65: GlaxoSmithKline Plc - Segment focus
  • Exhibit 66: GlaxoSmithKline Plc - Key offerings
  • Exhibit 67: GlaxoSmithKline Plc - Key customers
  • Exhibit 68: Granules India Ltd. - Vendor overview
  • Exhibit 69: Granules India Ltd. - Business segments
  • Exhibit 70: Granules India Ltd. - Organizational developments
  • Exhibit 71: Granules India Ltd. - Geographic focus
  • Exhibit 72: Granules India Ltd. - Segment focus
  • Exhibit 73: Granules India Ltd. - Key offerings
  • Exhibit 74: Granules India Ltd. - Key customers
  • Exhibit 75: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 76: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 77: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 78: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 79: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 80: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 81: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 82: Mylan NV - Vendor overview
  • Exhibit 83: Mylan NV - Product segments
  • Exhibit 84: Mylan NV - Organizational developments
  • Exhibit 85: Mylan NV - Geographic focus
  • Exhibit 86: Mylan NV - Segment focus
  • Exhibit 87: Mylan NV - Key offerings
  • Exhibit 88: Mylan NV - Key customers
  • Exhibit 89: Novartis AG - Vendor overview
  • Exhibit 90: Novartis AG - Business segments
  • Exhibit 91: Novartis AG - Organizational developments
  • Exhibit 92: Novartis AG - Geographic focus
  • Exhibit 93: Novartis AG - Segment focus
  • Exhibit 94: Novartis AG - Key offerings
  • Exhibit 95: Novartis AG - Key customers
  • Exhibit 96: Perrigo Co. Plc - Vendor overview
  • Exhibit 97: Perrigo Co. Plc - Business segments
  • Exhibit 98: Perrigo Co. Plc - Organizational developments
  • Exhibit 99: Perrigo Co. Plc - Geographic focus
  • Exhibit 100: Perrigo Co. Plc - Segment focus
  • Exhibit 101: Perrigo Co. Plc - Key offerings
  • Exhibit 102: Perrigo Co. Plc - Key customers
  • Exhibit 103: Pfizer Inc. - Vendor overview
  • Exhibit 104: Pfizer Inc. - Business segments
  • Exhibit 105: Pfizer Inc. - Organizational developments
  • Exhibit 106: Pfizer Inc. - Geographic focus
  • Exhibit 107: Pfizer Inc. - Segment focus
  • Exhibit 108: Pfizer Inc. - Key offerings
  • Exhibit 109: Pfizer Inc. - Key customers
  • Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 116: Validation techniques employed for market sizing
  • Exhibit 117: Definition of market positioning of vendors